The impact of corticosteroids on growth and bone health.
作者信息
Mushtaq T, Ahmed S F
机构信息
Dept of Integrative Biology, Roslin Institute, Edinburgh, UK.
出版信息
Arch Dis Child. 2002 Aug;87(2):93-6. doi: 10.1136/adc.87.2.93.
Abstract
摘要
相似文献
1
The impact of corticosteroids on growth and bone health.
Arch Dis Child. 2002 Aug;87(2):93-6. doi: 10.1136/adc.87.2.93.
2
Growth hormone treatment in children with rheumatic disease, corticosteroid induced growth retardation, and osteopenia.
Arch Dis Child. 2006 Jan;91(1):56-60. doi: 10.1136/adc.2004.069138. Epub 2005 Oct 13.
3
Glucocorticoid effects on statural growth.
Br J Rheumatol. 1993 May;32 Suppl 2:27-30. doi: 10.1093/rheumatology/32.suppl_2.27.
4
Animal models to explore the effects of glucocorticoids on skeletal growth and structure.
J Endocrinol. 2018 Jan;236(1):R69-R91. doi: 10.1530/JOE-17-0361. Epub 2017 Oct 19.
5
[Treatment with corticosteroids, bone mineral density and risk of fractures].
Vnitr Lek. 2003 Jan;49(1):12-4.
6
Over-the-counter Use of Glucocorticoids causing Severe Stunting in Siblings.
Indian Pediatr. 2019 Mar 15;56(3):251.
7
[Risks of inhaled glucocorticoids in infantile asthma].
Arch Bronconeumol. 1994 Aug-Sep;30(7):327-30.
8
Relation of osteopenia to glucocorticoid replacement therapy in Addison disease.
Ann Intern Med. 1994 Aug 1;121(3):236-7. doi: 10.7326/0003-4819-121-3-199408010-00018.
9
Bone growth mechanisms and the effects of cytotoxic drugs.
Arch Dis Child. 1999 Oct;81(4):360-4. doi: 10.1136/adc.81.4.360.
10
[Osteoporosis in chronic inflammatory bowel diseases--what is the value of fluoride therapy? Symposium: "Osteopenia, osteoporosis in chronic inflammatory bowel diseases". Saalfelden, 10 October 1998].
Dtsch Med Wochenschr. 1998 Dec;123(51-52 Suppl Osteoporos):1-4.
引用本文的文献
1
Patient Considerations when Using Ritlecitinib for Alopecia Areata in Adolescents: Guidance for the Clinicians.
Skin Appendage Disord. 2025 Jun;11(3):262-269. doi: 10.1159/000541392. Epub 2024 Nov 7.
2
Exploring the potential relationships between idiopathic scoliosis and various multifactorial diseases: a systematic scoping review.
Spine Deform. 2025 Apr 9. doi: 10.1007/s43390-025-01085-0.
3
Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial.
J Dermatol. 2025 Apr;52(4):603-614. doi: 10.1111/1346-8138.17539. Epub 2025 Mar 12.
4
Prevalence and predictors of stunting in children and adolescents aged 1-18 years with nephrotic syndrome attending Mulago Hospital, Uganda.
BMC Nephrol. 2025 Mar 3;26(1):110. doi: 10.1186/s12882-025-04025-2.
5
Children with autoimmune hepatitis receiving standard-of-care therapy demonstrate long-term obesity and linear growth delay.
Hepatol Commun. 2025 Feb 3;9(2). doi: 10.1097/HC9.0000000000000624. eCollection 2025 Feb 1.
6
Atopic dermatitis in childhood and pubertal development: A nationwide cohort study.
JAAD Int. 2024 Nov 22;19:21-31. doi: 10.1016/j.jdin.2024.09.018. eCollection 2025 Apr.
7
Short Course of Systemic Steroids for Acute Respiratory Diseases During Infancy and Final Adult Height, Weight, and BMI: Preliminary Results from a Prospective Cohort Study.
J Clin Med. 2025 Jan 9;14(2):387. doi: 10.3390/jcm14020387.
8
Real-world application of the pediatric Glucocorticoid Toxicity Index in childhood-onset lupus.
Semin Arthritis Rheum. 2024 Oct;68:152516. doi: 10.1016/j.semarthrit.2024.152516. Epub 2024 Jul 15.
9
Glucocorticoid Therapy in Acute Lymphoblastic Leukemia: Navigating Short-Term and Long-Term Effects and Optimal Regimen Selection.
Curr Hematol Malig Rep. 2024 Aug;19(4):175-185. doi: 10.1007/s11899-024-00735-w. Epub 2024 Jun 13.
10
Impact of childhood nephrotic syndrome on obesity and growth: a prospective cohort study.
Pediatr Nephrol. 2024 Sep;39(9):2667-2677. doi: 10.1007/s00467-024-06370-0. Epub 2024 Apr 18.
本文引用的文献
1
Effects of prolonged cortisone therapy on the statural growth, skeletal maturation and metabolic status of children.
N Engl J Med. 1956 Apr 5;254(14):636-41. doi: 10.1056/NEJM195604052541402.
2
Assessing the effect of intranasal steroids on growth.
J Allergy Clin Immunol. 2001 Jul;108(1 Suppl):S40-4. doi: 10.1067/mai.2001.115565.
3
Bony morbidity in children treated for acute lymphoblastic leukemia.
J Clin Oncol. 2001 Jun 15;19(12):3066-72. doi: 10.1200/JCO.2001.19.12.3066.
4
Normal bone mineral density after treatment for childhood acute lymphoblastic leukemia diagnosed between 1991 and 1998.
J Pediatr. 2001 Jun;138(6):898-904. doi: 10.1067/mpd.2001.113102.
5
Bone mineral decrements in survivors of childhood acute lymphoblastic leukemia: frequency of occurrence and risk factors for their development.
Leukemia. 2001 May;15(5):728-34. doi: 10.1038/sj.leu.2402078.
6
High dose, alternate day corticosteroids for systemic onset juvenile rheumatoid arthritis.
J Rheumatol. 2000 Aug;27(8):2018-24.
7
8
Bone mineral content and bone mineral metabolism: changes after growth hormone treatment in juvenile chronic arthritis.
J Rheumatol. 2000 Apr;27(4):1073-81.
9
Effects of a third intensification block of chemotherapy on bone and collagen turnover, insulin-like growth factor I, its binding proteins and short-term growth in children with acute lymphoblastic leukaemia.
Eur J Cancer. 1999 Jun;35(6):960-7. doi: 10.1016/s0959-8049(99)00060-x.
10
Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis.
Endocrinology. 1999 Oct;140(10):4382-9. doi: 10.1210/endo.140.10.7034.
Zotero 插件